middle.news
Why CLINUVEL Is Betting on CEO Wolgen to Lead Its Vitiligo Breakthrough
8:40am on Friday 20th of March, 2026 AEDT
•
Pharmaceuticals
Read Story
Why CLINUVEL Is Betting on CEO Wolgen to Lead Its Vitiligo Breakthrough
8:40am on Friday 20th of March, 2026 AEDT
Key Points
Strongest first half-year financial result with A$233 million cash reserves
Board unanimously retains CEO Philippe Wolgen for next 24-36 months
Vitiligo clinical program prioritised; PhotoCosmetic M-lines prelaunch delayed to 2027
Plans to upgrade US ADR program to Level II and pursue Nasdaq listing in H1 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE